Inhibiting breast cancer progression by exploiting TGFβ signaling

Current Drug Targets

Volumn 11, Issue 9, 2010, Pages 1089-1102

  Baxley, Sarah E ^a   Serra, Rosa ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Apoptosis; Breast cancer; Cytostatic; Immune regulation; Metastasis; Stem cell; TGF

Indexed keywords

ANTINEOPLASTIC AGENT; LY 2109761; LY 2157299; LY 364947; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CYTOSTASIS; DOWN REGULATION; HUMAN; METASTASIS; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING;

ANIMALS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; MOLECULAR TARGETED THERAPY; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD PROTEINS; STEM CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 78651278424     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010792006771     Document Type: Article

References (173)

1. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-8.
2. Serra R, Crowley CM. TGF-beta in mammary gland development and breast cancer. Breast Dis 2003; 18: 61-73.
3. Bottinger EP, Letterio JJ, Roberts AB. Biology of TGF-beta in knockout and transgenic mouse models. Kidney Int 1997; 51: 1355-60.
4. Pircher R, Jullien P, Lawrence DA. Beta-transforming growth factor is stored in human blood platelets as a latent high molecular weight complex. Biochem Biophys Res Commun 1986; 136: 30-7.
5. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003; 116: 217-24.
6. Koli K, Saharinen J, Hyytiainen M, Penttinen C, Keski-Oja J. Latency, activation, and binding proteins of TGF-beta. Microsc Res Tech 2001; 52: 354-62.
7. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000; 11: 59-69.
8. Lawler J, Sunday M, Thibert V, et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 1998; 101: 982-92.
9. Shi Y MJ. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685 - 700.
10. Derynck R. TGF-beta-receptor-mediated signaling. Trends Biochem Sci 1994; 19: 548-53.
11. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-beta receptor. Nature 1994; 370: 341-7.
12. Bandyopadhyay A, Zhu Y, Cibull M, Bao L, Chen C, Sun L. A soluble transforming growth factor beta type II receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res 1999; 59: 5041 - 46.
13. Padua D, Massague J. Roles of TGFbeta in metastasis. Cell Res 2009; 19: 89-102.
14. Hartsough MT, Mulder KM. Transforming growth factor beta activation of p44mapk in proliferating cultures of epithelial cells. J Biol Chem 1995; 270: 7117-24.
15. Frey RS, Mulder KM. TGFbeta regulation of mitogen-activated protein kinases in human breast cancer cells. Cancer Lett 1997; 117: 41-50.
16. Mucsi I, Skorecki KL, Goldberg HJ. Extracellular signal-regulated kinase and the small GTP-binding protein, Rac, contribute to the effects of transforming growth factor-beta1 on gene expression. J Biol Chem 1996; 271: 16567-72.
17. Simeone DM, Zhang L, Graziano K, et al. Smad4 mediates activation of mitogen-activated protein kinases by TGF-beta in pancreatic acinar cells. Am J Physiol Cell Physiol 2001; 281: C311-9.
18. Lee MK, Pardoux C, Hall MC, et al. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J 2007; 26: 3957-67.
19. Zavadil J, Bitzer M, Liang D, et al. Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proc Natl Acad Sci USA 2001; 98: 6686-91.
20. Davies M, Robinson M, Smith E, Huntley S, Prime S, Paterson I. Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. J Cell Biochem 2005; 95: 918-31.
21. McHenry PR, Vargo-Gogola, T. Pleiotropic Functions of Rho GTPase Signaling: a Trojan Horse or Achilles' Heel for Breast Cancer Treatment? Curr Drug Targets 2010; 11(9): 1043-58.
22. Edlund S LM, Heldin CH, Aspenstrom P. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell 2002; 13: 902-14.
23. Barrios-Rodiles M, Brown KR, Ozdamar B, et al. High through-put mapping of a dynamic signaling network in mammalian cells. Science 2005; 307: 1621-25.
24. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Cell Biol 2007; 19: 142-9.
25. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001; 412: 346-51.
26. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res 2009; 19: 128-39.
27. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000; 275: 36803-10.
28. Shin I, Bakin AV, Rodeck U, Brunet A, Arteaga CL. Transforming growth factor beta enhances epithelial cell survival via Aktdependent regulation of FKHRL1. Mol Biol Cell 2001; 12: 3328-39.
29. Vinals F, Pouyssegur J. Transforming growth factor beta1 (TGFbeta1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-alpha signaling. Mol Cell Biol 2001; 21: 7218-30.
30. Wilkes MC, Mitchell H, Penheiter SG, et al. Transforming growth factor-beta activation of phosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21-activated kinase-2. Cancer Res 2005; 65: 10431-40.
31. Lamouille S, Derynck R. Cell size and invasion in TGF-betainduced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 2007; 178: 437-51.
32. Valderrama-Carvajal H, Cocolakis E, Lacerte A, et al. Activin/TGF-beta induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIP. Nat Cell Biol 2002; 4: 963-9.
33. Chen RH, Su YH, Chuang RL, Chang TY. Suppression of transforming growth factor-beta-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway. Oncogene 1998; 17: 1959-68.
34. Song K, Wang H, Krebs TL, Danielpour D. Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation. EMBO J 2006; 25: 58-69.
35. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005; 19: 2783-810.
36. Yan X, Liu Z, Chen Y. Regulation of TGF-beta signaling by Smad7. Acta Biochim Biophys Sin (Shanghai) 2009; 41: 263-72.
37. Inoue Y, Imamura T. Regulation of TGF-beta family signaling by E3 ubiquitin ligases. Cancer Sci 2008; 99: 2107-12.
38. Kavsak P, Rasmussen RK, Causing CG, et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 2000; 6: 1365-75.
39. Ebisawa T, Fukuchi M, Murakami G, et al. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem 2001; 276: 12477-80.
40. Ross S, Hill CS. How the Smads regulate transcription. Int J Biochem Cell Biol 2008; 40: 383-408.
41. Lin X, Duan X, Liang YY, et al. PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell 2006; 125: 915-28.
42. Tian M, Schiemann WP. The TGF-beta paradox in human cancer: an update. Future Oncol 2009; 5: 259-71.
43. Gobbi H, Arteaga CL, Jensen RA, et al. Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in situ and invasive carcinomas. Histopathology 2000; 36: 168-77.
44. Lucke CD, Philpott A, Metcalfe JC, et al. Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer. Cancer Res 2001; 61: 482-85.
45. Chen T CD, Garrigue-Antar L, Reiss M. Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res 1998; 58: 4805-10.
46. Jeruss JS, Sturgis CD, Rademaker AW, Woodruff TK. Downregulation of activin, activin receptors, and Smads in high-grade breast cancer. Cancer Res 2003; 63: 3783-90.
47. Xie W, Mertens JC, Reiss DJ, et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res 2002; 62: 497-505.
48. Benson J. Role of Transforming growth factor beta in breast carcinogenesis. Lancet Oncol 2004; 5: 229-39.
49. Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM, Berthois Y. Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival. Br J Cancer 2006; 94: 239-46.
50. Grau AM, Wen W, Ramroopsingh DS, et al. Circulating transforming growth factor-beta-1 and breast cancer prognosis: results from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 2008; 112: 335-41.
51. Mu L, Katsaros D, Lu L, et al. TGF-beta1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. Br J Cancer 2008; 99: 1357-63.
52. Chod J, Zavadova E, Halaska MJ, Strnad P, Fucikova T, Rob L. Preoperative transforming growth factor-beta 1 plasma levels in operable breast cancer patients. Eur J Gynaecol Oncol 2008; 29: 613-16.
53. Domschke C, Schuetz F, Ge Y, et al. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res 2009; 69: 8420-28.
54. Zheng W. Genetic polymorphisms in the transforming growth factor-beta signaling pathways and breast cancer risk and survival. Methods Mol Biol 2009; 472: 265-77.
55. Ziv E, Cauley J, Morin PA, Saiz R, Browner WS. Association between the T29C polymorphism in the transforming growth factor beta1 gene and breast cancer among elderly white women: The Study of Osteoporotic Fractures. JAMA 2001; 285: 2859-63.
56. Dunning AM, Ellis PD, McBride S, et al. A transforming growth factor beta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003; 63: 2610-15.
57. Le Marchand L, Haiman CA, van den Berg D, Wilkens LR, Kolonel LM, Henderson BE. T29C polymorphism in the transforming growth factor beta1 gene and postmenopausal breast cancer risk: the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev 2004; 13: 412-15.
58. Kaklamani VG, Baddi L, Liu J, et al. Combined genetic assesment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res 2005; 65: 3454-61.
59. Rebbeck TR, Antoniou AC, Llopis TC, et al. No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. Breast Cancer Res Treat 2009; 115: 185-92.
60. Feigelson HS, Patel AV, Diver WR, Stevens VL, Thun MJ, Calle EE. Transforming growth factor beta receptor type I and transforming growth factor beta1 polymorphisms are not associated with postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 1236-7.
61. Krippl P, Langsenlehner U, Renner W, et al. The L10P polymorphism of the transforming growth factor-beta1 gene is not associated with breast cancer risk. Cancer Lett 2003; 201: 181-4.
62. Shin A, Shu XO, Cai Q, Gao YT, Zheng W. Genetic polymorphisms of the Trasnforming Growth Factor-beta1 gene and breast cancer risk: a possible dual role at different cancer stages. Cancer Epidemiol Biomarkers Prev 2005; 14: 1567-70.
63. Rajkumar T, Samson M, Rama R, et al. TGFbeta1(Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy. Breast Cancer Res Treat 2008; 112: 81-7.
64. Baxter SW, Choong DY, Eccles DM, Cambell IG. Transforming growth factor beta receptor I polyalanine polymorphism and exon 5 mutation analysis in breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 211-4.
65. Jin Q, Hemminki K, Grzybowska E, et al. Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers. Int J Cancer 2004; 112: 94-9.
66. Pasche B, Kolachana P, Nafa K, et al. TbetaR-I(6A) is a candidate tumor susceptibility allele. Cancer Res 1999; 59: 5678-82.
67. Chen T, Jackson CR, Link A, et al. Int7G24A variant of transforming growth factor-beta receptor type I is associated with invasive breast cancer. Clin Cancer Res 2006; 12: 392-7.
68. Robinson SD, Silberstein GB, Roberts AB, Flanders KC, Daniel CW. Regulated expression and growth inhibitory effects of transforming growth factor-beta isoforms in mouse mammary gland development. Development 1991; 113: 867-78.
69. Flanders KC, Wakefield LM. Transforming growth factor-(beta)s and mammary gland involution; functional roles and implications for cancer progression. J Mammary Gland Biol Neoplasia 2009; 14: 131-44.
70. Faure E, Heisterkamp N, Groffen J, Kaartinen V. Differential expression of TGF-beta isoforms during postlactational mammary gland involution. Cell Tissue Res 2000; 300: 89-95.
71. Nguyen AV, Pollard JW. Transforming growth factor beta3 induces cell death during the first stage of mammary gland involution. Development 2000; 127: 3107-18.
72. Strange R, Li F, Saurer S, Burkhardt A, Friis RR. Apoptotic cell death and tissue remodelling during mouse mammary gland involution. Development 1992; 115: 49-58.
73. Serra R, Crowley MR. Mouse models of transforming growth factor beta impact in breast development and cancer. Endocr Relat Cancer 2005; 12: 749-60.
74. Pierce DF Jr., Johnson MD, Matsui Y, et al. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. Genes Dev 1993; 7: 2308-17.
75. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 2003; 100: 8430-5.
76. Bottinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res 1997; 57: 5564-70.
77. Yang Y, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice again metastasis without adverse side effects. J Clin Invest 2002; 109: 1607-15.
78. Forrester E, Chytil A, Bierie B, et al. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 2005; 65: 2296-302.
79. Jhappan C, Geiser AG, Kordon EC, et al. Targeting expression of a transforming growth factor beta 1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. EMBO J 1993; 12: 1835-45.
80. Muraoka-Cook RS, Kurokawa H, Koh Y, et al. Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 2004; 64: 9002-11.
81. Gorska AE, Joseph H, Derynck R, Moses HL, Serra R. Dominantnegative interference of the transforming growth factor beta type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice. Cell Growth Differ 1998; 9: 229-38.
82. Gorska AE, Jensen RA, Shyr Y, Aakre ME, Bhowmick NA, Moses HL. Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am J Pathol 2003; 163: 1539-49.
83. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992; 12: 954-61.
84. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992; 89: 10578-82.
85. Matsui Y, Halter SA, Holt JT, Hogan BL, Coffey RJ. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 1990; 61: 1147-55.
86. Medina D. Mammary tumorigenesis in chemical carcinogen-treated mice. I. Incidence in BALB-c and C57BL mice. J Natl Cancer Inst 1974; 53: 213-21.
87. Alexandrow MG, Moses HL. Transforming growth factor beta and cell cycle regulation. Cancer Res 1995; 55: 1452-7.
88. Heldin CH, Landstrom M, Moustakas A. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 2009; 21: 166-76.
89. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGFbeta in homeostasis and cancer. Nat Rev Cancer 2003; 3: 807-21.
90. Ewan KB, Oketch-Rabah HA, Ravani SA, Shyamala G, Moses HL, Barcellos-Hoff MH. Proliferation of estrogen receptor-alphapositive mammary epithelial cells is restrained by transforming growth factor-beta1 in adult mice. Am J Pathol 2005; 167: 409-17.
91. Grimm SL, Rosen JM. Stop! In the name of transforming growth factor-beta: keeping estrogen receptor-alpha-positive mammary epithelial cells from proliferating. Breast Cancer Res 2006; 8: 106.
92. Kordon EC, McKnight RA, Jhappan C, Hennighausen L, Merlino G, Smith GH. Ectopic TGF beta 1 expression in the secretory mammary epithelium induces early senescence of the epithelial stem cell population. Dev Biol 1995; 168: 47-61.
93. Bailey JP, Nieport KM, Herbst MP, Srivastava S, Serra RA, Horseman ND. Prolactin and transforming growth factor-beta signaling exert opposing effects on mammary gland morphogenesis, involution, and the Akt-forkhead pathway. Mol Endocrinol 2004; 18: 1171-84.
94. Nam JS, Terabe M, Kang MJ, et al. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008; 68: 3915-23.
95. Motyl T, Gajkowska B, Zarzynska J, Gajewska M, Lamparska-Przybysz M. Apoptosis and autophagy in mammary gland remodeling and breast cancer chemotherapy. J Physiol Pharmacol 2006; 57 Suppl 7: 17-32.
96. Kiyono K, Suzuki HI, Matsuyama H, et al. Autophagy is activated by TGF-beta and potentiates TGF-beta-mediated growth inhibition in human hepatocellular carcinoma cells. Cancer Res 2009; 69: 8844-52.
97. Mizushima N, Klionsky DJ. Protein turnover via autophagy: implications for metabolism. Annu Rev Nutr 2007; 27: 19-40.
98. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-8.
99. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7.
100. Pal A, Valdez KE, Carletti MZ, Fariba B. Targeting the preparator: breast cancer stem cell therapeutics. Curr Drug Targets 2010; 11(9): 1147-56.
101. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-68.
102. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-8.
103. Shackleton M, Vaillant F, Simpson KJ, et al. Generation of a functional mammary gland from a single stem cell. Nature 2006; 439: 84-8.
104. Stingl J, Eirew P, Ricketson I, et al. Purification and unique properties of mammary epithelial stem cells. Nature 2006; 439: 993-7.
105. Chepko G, Smith GH. Mammary epithelial stem cells: our current understanding. J Mammary Gland Biol Neoplasia. 1999; 4: 35-52.
106. Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7: 1028-34.
107. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253-70.
108. Liu JC, Deng T, Lehal RS, Kim J, Zacksenhaus E. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors. Cancer Res 2007; 67: 8671-81.
109. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-67.
110. Li H, Xu D, Li J, Berndt MC, Liu JP. Transforming growth factor beta suppresses human telomerase reverse transcriptase (hTERT) by Smad3 interactions with c-Myc and the hTERT gene. J Biol Chem 2006; 281: 25588-600.
111. Cassar L, Nicholls C, Pinto AR, Li H, Liu JP. Bone morphogenetic protein-7 induces telomerase inhibition, telomere shortening, breast cancer cell senescence, and death via Smad3. FASEB J 2009; 23: 1880-92.
112. Tang B, Yoo N, Vu M, et al. Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and comitted progeny in a breast cancer xenograft model. Cancer Res 2007; 67: 8643-52.
113. Boulanger CA, Smith GH. Reducing mammary cancer risk through premature stem cell senescence. Oncogene 2001; 20: 2264-72.
114. Boulanger CA, Wagner KU, Smith GH. Parity-induced mouse mammary epithelial cells are pluripotent, self-renewing and sensitive to TGF-beta1 expression. Oncogene. 2005; 24: 552-60.
115. Siwko SK, Dong J, Lewis MT, Liu H, Hilsenbeck SG, Li Y. Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells--implications for pregnancy-induced protection against breast cancer. Stem Cells 2008; 26: 3205-9.
116. Roarty K, Baxley SE, Crowley MR, Frost AR, Serra R. Loss of TGF-beta or Wnt5a results in an increase in Wnt/beta-catenin activity and redirects mammary tumour phenotype. Breast Cancer Res 2009; 11: R19.
117. Prosperi JR, Goss KH. A Wnt-ow of opportunity: targeting the Wnt/β-catenin pathway in breast cancer. Curr Drug Targets 2010; 11(9): 1074-88.
118. Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007; 11: 259-73.
119. Bierie B, Stover DG, Abel TW, et al. Transforming growth factorbeta regulates mammary carinoma cell survival and interaction with the adjacent microenvironment. Cancer Res 2008; 68: 1809-19.
120. Crowley MR, Frost A, Chen DT, Baffi MO, Nicola T, Serra R. Transforming growth factor-beta signaling helps specify tumor type in DMBA and hormone-induced mammary cancers. Differentiation 2006; 74: 40-52.
121. Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW, Waltham M. Vimentin and epithelial-mesenchymal transition in human breast cancer--observations in vitro and in vivo. Cells Tissues Organs 2007; 185: 191-203.
122. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-54.
123. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009; 19: 156-72.
124. Welch DR, Fabra A, Nakajima M. Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 1990; 87: 4391-8.
125. Muraoka-Cook RS, Shin I, Yi JY, et al. Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene 2006; 25: 3408-23.
126. Buck MB, Fritz P, Dippon J, Zugmaier G, Knabbe C. Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin Cancer Res 2004; 10: 491-8.
127. Dalal BI, Keown PA, Greenberg AH. Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 1993; 143: 381-9.
128. Yin JJ, Selander K, Chirgwin JM, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999; 103: 197-206.
129. McEarchern JA, Kobie JJ, Mack V, et al. Invasion and metastasis of a mammary tumor involves TGF-beta signaling. Int J Cancer 2001; 91: 76-82.
130. Tang B, Vu M, Booker T, et al. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 2003; 112: 1116-24.
131. Kang Y, He W, Tulley S, et al. Breast cancer bone metastasis mediated by the Smad tumor suppresor pathway. Proc Natl Acad Sci USA 2005; 102: 13909-14.
132. Javelaud D, Mohammad KS, McKenna CR, et al. Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res 2007; 67: 2317-24.
133. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996; 98: 1544-9.
134. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther 2007; 6: 2609-17.
135. Adorno M, Cordenonsi M, Montagner M, et al. A mutantp53/ Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009; 137: 87 - 98.
136. Noel A, Foidart JM. The role of stroma in breast carcinoma growth in vivo. J Mammary Gland Biol Neoplasia 1998; 3: 215-25.
137. Tlsty TD, Hein PW. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 2001; 11: 54-9.
138. Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. Science 2002; 296: 1046-9.
139. Barcellos-Hoff MH, Ravani SA. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res 2000; 60: 1254-60.
140. Barcellos-Hoff MH. Radiation-induced transforming growth factor beta and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res 1993; 53: 3880-6.
141. Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest 1994; 93: 892-9.
142. Ehrhart EJ, Segarini P, Tsang ML, Carroll AG, Barcellos-Hoff MH. Latent transforming growth factor beta1 activation in situ: quantitative and functional evidence after low-dose gammairradiation. FASEB J 1997; 11: 991-1002.
143. Cheng N, Bhowmick N, Chytil A, et al. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP-, and HGFmediated signaling networks. Oncogene 2005; 24: 5053 - 68.
144. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003; 100: 8621-3.
145. Forrester E, Chytil A, Bierie B, et al. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 2005; 65: 2296-302.
146. Cheng N, Chytil A, Shyr Y, Joly A, Moses H. Enchanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis. Cancer Res 2007; 67: 4869 - 77.
147. Yang L, Huang J, Ren X, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13: 23 - 35.
148. Bierie B, Moses HL. Gain or loss of TGFbeta signaling in mammary carcinoma cells can promote metastasis. Cell Cycle 2009; 8: 3319-27.
149. Goldberg JE, Schwertfeger KL. Proinflammatory Cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets 2010; 11(9): 1133-46.
150. Bierie B, Chung CH, Parker JS, et al. Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest 2009; 119: 1571-82.
151. Muraoka R, Dumont N, Ritter C, et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002; 109: 1551 - 59.
152. Tan AR, Alexe G, Reiss M. Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat 2009; 115: 453-95.
153. Arteaga C, Carty-Dugger T, Moses H, Hurd S, Pietenpol J. Transforming growth factor beta 1 can induce estrogenindependent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ 1993; 4: 193-201.
154. Carano R, Li Y, Bao M, et al. Effect of anti-TGF-beta antibodies in syngeneic mouse models of metastasis. J Musculoskelet Neuronal Interact 2004; 4: 377 - 78.
155. Nam JS, Suchar AM, Kang MJ, et al. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res 2006; 66: 6327-35.
156. Nam JS, Terabe M, Mamura M, et al. An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 2008; 68: 3835-43.
157. Pinkas J, Teicher BA. TGF-beta in cancer and as a therapeutic target. Biochem Pharmacol 2006; 72: 523-9.
158. Bandyopadhyay A, Lopez-Casillas F, Malik S, et al. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xeno-graft. Cancer Res 2002; 62: 4690-95.
159. Bandyopadhyay A, Zhu Y, Malik S, et al. Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 2002; 21: 3541-51.
160. Huse M, Muir T, Xu L, Chen Y, Kuriyan J, Massague J. The TGF beta receptor activation process: an inhibitor to substrate-binding switch. Mol Cell 2001; 8: 671-82.
161. Ge R, Rajeev V, Ray P, et al. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res 2006; 12: 4315-30.
162. Bueno L, de Alwis D, Pitou C, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer 2008; 44: 142-50.
163. Li H, McMillen W, Heap C, et al. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. J Med Chem 2008; 51: 2302-06.
164. Bandyopadhyay A, Agyin J, Wang L, et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factorbeta type I receptor kinase inhibitor. Cancer Res 2006; 66: 6714-21.
165. Ehata S, Hanyu A, Fujime M, et al. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 2007; 98: 127-33.
166. Chakrabarti R, Subramaniam V, Abdalla S, Jothy S, Prud'homme GJ. Tranilast inhibits the growth and metastasis of mammary carcinoma. Anticancer Drugs 2009; 20: 334-45.
167. Hau P, Jachimczak P, Schlingensiepen R, et al. Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP12009 in clinical development against malignant tumors. Recent Results Cancer Res 2006; 177: 137-50.
168. Morris J, Shapiro G, Tan A, et al. Phase 1/2 study of GC1008: a human anti transforming growth factor-beta monoclonal antibody in patients with advanced malignant melanoma or recal cell carcinoma. J Clin Oncol 2008; 26: Abstract#9028.
169. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-25.
170. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-60.
171. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-lik cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10: R25.
172. Mishra L, Banker T, Murray J, et al. Liver stem cells and hepatocellular carcinoma. Hepatology 2009; 49: 318-29.
173. Mishra L, Shetty K, Tang Y, Stuart A, Byers SW. The role of TGFbeta and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene 2005; 24: 5775-89.